IGFBP1 in Epithelial Circulating Tumor Cells as a Potential Response Marker to Selective Internal Radiation Therapy in Hepatocellular Carcinoma

References

• Llovet JM , BurroughsA, BruixJ. Hepatocellular carcinoma.Lancet362 (9399), 1907 – 1917 (2003).
   PubMed Web of Science ®Google Scholar
• Jemal A , BrayF, CenterMM, FerlayJ, WardE, FormanD. Global cancer statistics.CA Cancer J. Clin.61 (2), 69 – 90 (2011).
   PubMed Web of Science ®Google Scholar
• Winton T , LivingstonR, JohnsonDet al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N. Engl. J. Med. 352 (25), 2589 – 2597 (2005).
   PubMed Web of Science ®Google Scholar
• Olaussen KA , DunantA, FouretPet al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N. Engl. J. Med. 355 (10), 983 – 991 (2006).
   PubMed Web of Science ®Google Scholar
• Sangro B , BilbaoJI, BoanJet al. Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 66 (3), 792 – 800 (2006).
   PubMed Web of Science ®Google Scholar
• Lau WY , LaiEC, LeungTW. Current role of selective internal irradiation with yttrium-90 microspheres in the management of hepatocellular carcinoma: a systematic review.Int. J. Radiat. Oncol. Biol. Phys.81 (2), 460 – 467 (2011).
   PubMed Web of Science ®Google Scholar
• Sun YF , YangXR, ZhouJ, QiuSJ, FanJ, XuY. Circulating tumor cells: advances in detection methods, biological issues, and clinical relevance.J. Cancer Res. Clin. Oncol.137 (8), 1151 – 1173 (2011).
   PubMed Web of Science ®Google Scholar
• Allard WJ , MateraJ, MillerMCet al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin. Cancer Res. 10 (20), 6897 – 6904 (2004).
   PubMed Web of Science ®Google Scholar
• Moldenhauer G , MomburgF, MollerP, SchwartzR, HammerlingGJ. Epithelium-specific surface glycoprotein of Mr 34,000 is a widely distributed human carcinoma marker. Br. J. Cancer56 (6), 714 – 721 (1987).
   PubMed Web of Science ®Google Scholar
• Zhang N , LiX, WuCWet al. microRNA-7 is a novel inhibitor of YY1 contributing to colorectal tumorigenesis. Oncogene 32 (42), 5078 – 5088 (2012).
   PubMed Web of Science ®Google Scholar
• Cristofanilli M , BuddGT, EllisMJet al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N. Engl. J. Med. 351 (8), 781 – 791 (2004).
   PubMed Web of Science ®Google Scholar
• Gauler TC , TheegartenD, ParrAet al. Decrease of circulating tumor cells associates with response to platinum-based chemotherapy in patients with non-small cell lung cancer, but not with small cell lung cancer. J. Thorac. Oncol. 6 (6), S1114 – S1114 (2011).
   Web of Science ®Google Scholar
• Waguri N , SudaT, NomotoMet al. Sensitive and specific detection of circulating cancer cells in patients with hepatocellular carcinoma; detection of human telomerase reverse transcriptase messenger RNA after immunomagnetic separation. Clin. Cancer Res. 9 (8), 3004 – 3011 (2003).
   PubMed Web of Science ®Google Scholar
• Xu W , CaoL, ChenLet al. Isolation of circulating tumor cells in patients with hepatocellular carcinoma using a novel cell separation strategy. Clin. Cancer Res. 17 (11), 3783 – 3793 (2011).
   PubMed Web of Science ®Google Scholar
• Vona G , EstepaL, BeroudCet al. Impact of cytomorphological detection of circulating tumor cells in patients with liver cancer. Hepatology 39 (3), 792 – 797 (2004).
   PubMed Web of Science ®Google Scholar
• Guo J , YaoF, LouYet al. Detecting carcinoma cells in peripheral blood of patients with hepatocellular carcinoma by immunomagnetic beads and RT-PCR. J. Clin. Gastroenterol. 41 (8), 783 – 788 (2007).
   PubMed Web of Science ®Google Scholar
• Schulze K , BenekenC, StauferKet al. Detection of Epcam-positive circulating tumor cells in patients with hepatocellular carcinoma – a pilot study. Hepatology 54, 1357a – 1357a (2011).
   Web of Science ®Google Scholar
• Nel I , BabaHA, ErtleJet al. Individual profiling of circulating tumor cell composition and therapeutic outcome in patients with hepatocellular carcinoma. Transl. Oncol. 6 (4), 420 – 428 (2013).
   PubMed Web of Science ®Google Scholar
• Simon F , BockhornM, PrahaCet al. Deregulation of HIF1-alpha and hypoxia-regulated pathways in hepatocellular carcinoma and corresponding non-malignant liver tissue-influence of a modulated host stroma on the prognosis of HCC. Langenbecks Arch. Surg. 395 (4), 395 – 405 (2010).
   PubMed Web of Science ®Google Scholar
• Sobin LH . TNM: evolution and relation to other prognostic factors.Semin. Surg. Oncol.21 (1), 3 – 7 (2003).
   PubMedGoogle Scholar
• Therasse P , ArbuckSG, EisenhauerEAet al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl Cancer Inst. 92 (3), 205 – 216 (2000).
   PubMed Web of Science ®Google Scholar
• Hoffmann AC , DanenbergKD, TaubertH, DanenbergPV, WuerlP. A three-gene signature for outcome in soft tissue sarcoma.Clin. Cancer Res.15 (16), 5191 – 5198 (2009).
   PubMed Web of Science ®Google Scholar
• Hoffmann A-C , VallboehmerD, GrimmingerPet al. Preoperative survivin mRNA detection in peripheral blood is an independent predictor of outcome in esophageal carcinoma. Pharmacogenomics 11 (3), 341 – 347 (2010).
   PubMed Web of Science ®Google Scholar
• Hoffmann A-C , WildP, LeichtCet al. MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy. Neoplasia 12 (8), 628 – 636 (2010).
   PubMed Web of Science ®Google Scholar
• Henrich CJ , BudhuA, YuZet al. High-throughput screening for identification of inhibitors of EpCAM-dependent growth of hepatocellular carcinoma cells. Chem. Biol. Drug Design 82 (2), 131 – 139 (2013).
   PubMed Web of Science ®Google Scholar
• Sun YF , XuY, YangXRet al. Circulating stem cell-like EpCAM(+) tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection. Hepatology 57 (4), 1458 – 1468 (2012).
   Web of Science ®Google Scholar
• Zhou L , LiuJ, LuoF. Serum tumor markers for detection of hepatocellular carcinoma.World J. Gastroenterol.12 (8), 1175 – 1181 (2006).
   PubMed Web of Science ®Google Scholar
• Gong Y , CuiL, MinukGY. The expression of insulin-like growth factor binding proteins in human hepatocellular carcinoma.Mol. Cell. Biochem.207 (1–2), 101 – 104 (2000).
   PubMed Web of Science ®Google Scholar